BREAST CANCER

Dr Hart explains the different adjuvant therapy options for patients with HR+ breast cancer.

Lowell Hart, MD, FACP, introduces our patient case, a 54-year-old woman with ER+/PR+ breast cancer, and discusses his strategy and the risk of recurrence for the disease.

During a live virtual event, Lowell Hart, MD, discussed the findings of the monarchE trial of abemaciclib in high-risk patients with early breast cancer.

Lee Schwartzberg, MD, discusses the results of the KEYNOTE-522 trial of pembrolizumab in patients with early triple-negative breast cancer.

Research is ongoing to combat key resistance mechanisms, with new data recently presented by Sara A. Hurvitz, MD, FACP, and other oncologists and investigators during the 2021 San Antonio Breast Cancer Symposium.

Debu Tripathy, MD, said the 39th Annual Miami Breast Cancer Conference is always a well-rounded meeting.

During a live virtual event, Lowell Hart, MD, discussed the results of the monarchE trial of abemaciclib in patients with node-positive, hormone receptor–positive, HER2-negative, high-risk early breast cancer.

Gedatolisib has earned attention from the FDA after demonstrating encouraging efficacy and safety in a phase 1b clinical trial.

Enobosarm has been granted fast track designation from the FDA and is being explored alone and in combination with abemaciclib in 2 phase 3 clinical trials.

During a live virtual event, Joyce O'Shaughnessy, MD, discussed participants' experiences with the tolerability of sacituzumab govitecan in patients with metastatic triple-negative breast cancer. The participants also discussed their approaches to molecular testing for biomarkers at the time of disease relapse or progression.

During a live virtual event, Joyce O'Shaughnessy, MD, discussed treatment options for a patient with metastatic triple-negative breast cancer whose disease recurred 8 months after receiving adjuvant therapy.

Alexandra Higgins,MD, discusses the association of hepatopulmonary syndrome with the long-term use of ado-trastuzumab emtansine.

In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.

Two oncologists explain how patients can better understand the NCCN Clinical Practice Guidelines.

Two oncologists discuss the NCCN Clinical Practice Guidelines for triple-negative breast cancer.

Findings from the INSEMA study show that patients who received either sentinel lymph node biopsy or complete axillary lymph node dissection experienced differences in breast and arm symptoms compared with patients who did not.

In the phase 2 I-SPY 2 platform trial, receipt of targeted neoadjuvant chemotherapy did not appear to be based on race.

Adverse events in patients with high-risk HER2-negative early breast cancer treated with chemotherapy before olaparib may be resolved after therapy is complete.

Circulating tumor DNA should be used early and often by physcians who treat patients with early-stage triple-negative breast cancer.

Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.

Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.

Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.

Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.

Phase 3 results from a cohort of patients in China show a progression-free survival benefit with entinostat/exemestane.